title: BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
abstract: The treatment of chronic lymphocytic leukemia (CLL) with inhibitors targeting B cell receptor signaling and other survival mechanisms holds great promise. Especially the early clinical success of Ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase (BTK), has received widespread attention. In this review we will focus on the fundamental and clinical aspects of BTK inhibitors in CLL, with emphasis on Ibrutinib as the best studied of this class of drugs. Furthermore, we summarize recent laboratory as well as clinical findings relating to the first cases of Ibrutinib resistance. Finally, we address combination strategies with Ibrutinib, and attempt to extrapolate its current status to the near future in the clinic.
authors: 1] Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands [2] Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Academic Medical Center, Amsterdam, The Netherlands.
authors: M
authors: M
authors: Spaargaren
authors: Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors: M F M
authors: MF
authors: de Rooij
authors: 1] Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Academic Medical Center, Amsterdam, The Netherlands [2] Department of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors: A P
authors: AP
authors: Kater
authors: 1] Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Academic Medical Center, Amsterdam, The Netherlands [2] Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors: E
authors: E
authors: Eldering
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D011947:Receptors, Antigen, B-Cell / Q000037:antagonists & inhibitors*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; D011947:Receptors, Antigen, B-Cell; C551803:ibrutinib; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human; D000225:Adenine